Trial Profile
A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary) ; Clopidogrel; Prasugrel
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Acronyms BRIDGE
- Sponsors Medicines Company
- 26 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinialTrials.gov
- 28 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov